A Singapore digital therapeutics company is teaming up with a top US hospital in an innovative plan to use data from wearable biosensors to help improve the level of care patients receive at home.
Biofourmis CEO Kuldeep Singh Rajput said the collaboration will see the Singapore company work with USA based Brigham and Women’s Hospital to “enhance and co-develop new predictive models for monitoring acutely ill patients’ suffering from multiple conditions such as heart failure, pneumonia, Chronic obstructive pulmonary disease (COPD), and atrial fibrillation at home”. At the core of the development is Biovitals proprietary analytics engine.
Biovitals uses advanced machine learning to learn a patient’s physiology and then dynamically build a personalised physiology signature that can detect subtle physiological changes that may predict a patient’s health. The programme will also use Biofourmis’ RhythmAnalytics platform to detect dozens of different cardiac arrhythmias.
Brigham and Women’s Hospital is the largest hospital of the Longwood Medical and Academic Area in Boston, Massachusetts, and is Harvard Medical School’s second largest teaching affiliate.
Under Brigham’s Home Hospital Program patients are cared for at home, rather than in a hospital. Brigham’s team of doctors, nurses and clinical staff supplement their work with monitoring technology to help them provide the right care at the right time. The hospital has cared for more than 200 patients at home over a period of about two years, and was this year was recognised in the top 20 on US News & World Report’s ‘2018 Best Hospitals Honor Roll’.
Researcher and lead for Brigham and Women’s Home Hospital Program, David Levine, said the Biovitals analytics engine will be used to harness and clinically utilise the vast quantity of biometric data the home hospital team collects.
“Our home hospital team is hoping to improve care for our patients by creating a suite of highly clinically-useful algorithms that can predict deterioration and improvement for those who are acutely ill”, Dr Levine said.
Biovitals uses software, along with wearable biosensors, adjunctive pharmacotherapy and live clinical support, to manage patients suffering heart failure.
Using advanced machine learning, it builds a “physiology signature” that can detect subtle changes that may predict clinical exacerbation days in advance of a critical event.
Preliminary pilot data in a randomised clinical trial has found similar quality, safety, and experience outcomes as those in the hospital at about half the cost.
Feature photo supplied
- Cardiac Insight partners with VivoSense to expand use of its wearable cardiac sensors (Cardiac Rhythm News)
- Biosensor Market Expected to Be US$ 26 Billion by 2022 (Market Watch)
- Smart watches, fitness trackers and the NHS: Are wearables just what the doctor ordered? (ZD Net)
A a professional photographer since the days of film, he holds a Bachelor of Arts in Photomedia and a Postgraduate Diploma in Journalism.